Targets In-Depth Focus 2017
Posted: 5 June 2017 | Drug Target Review | No comments yet
Included in this Targets In-Depth Focus: Intracellular target validation in cellular systems; New drug targets identified to defend against chlamydia infections using CRISPR and stem cells; Novel solutions for tough targets with real bite…
- Intracellular target validation in cellular systems
Paul Grant, Venomtech - New drug targets identified to defend against chlamydia infections using CRISPR and stem cells
Amy Yeung, Wellcome Trust Sanger Institute - Novel solutions for tough targets with real bite
Steve Trim, Venomtech
This Targets In-Depth Focus is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Drug Development, Target Validation
Related conditions
Chlamydia
Related organisations
Charles River Laboratories, Venomtech, Wellcome Trust Sanger Institute
Related people
Dr Amy Yeung, Paul Grant, Steve Trim
